Document is current

Article History

First Online: 18 April 2020

Compliance with Ethical Standards

:

: The authors have no further conflict of interest to declare. Louis Létinier is a co-founder of Synapse Medicine (). Synapse Medicine played no role in the study.

: V.L. was a beneficiary of a specific grant from the <i>Fondation pour la Recherche Médicale</i> (FRM). A.P. is the coordinator of the DRUGS Systematised Assessment in real-liFe Environment (DRUGS-SAFE) program funded by the <i>Agence Nationale de Sécurité du Médicament et des Produits de Santé</i> (ANSM). The present study was included in the DRUGS-SAFE program. This program aims at providing an integrated system allowing the concomitant monitoring of drug use and safety in France. The potential impact of drugs, frailty of populations and seriousness of risks drive the research program. The funding sources played no role in the design and interpretation of this study. This publication represents the views of the authors and does not necessarily represent the opinion of ANSM or the FRM.

: Publicly sharing EGB data is forbidden by law according to The French national data protection agency (<i>Commission Nationale de l’Informatique et des Libertés</i>, CNIL); regulatory decisions AT/CPZ/SVT/JB/DP/CR05222O of June 14, 2005 and DP/CR071761 of August 28, 2007. To request data access please contact The National Institute for Health Data (Institut National des Données de Santé, INDS).